novaferon
novel
protein
drug
approv
treatment
chronic
hepat
b
china
exhibit
potent
antivir
activ
aim
determin
effect
novaferon
vitro
conduct
random
openlabel
parallel
group
studi
explor
antivir
effect
novaferon
laboratori
inhibit
novaferon
viral
replic
cell
infect
entri
healthi
cell
determin
antivir
effect
novaferon
evalu
patient
treatment
novaferon
novaferon
plu
lopinavirritonavir
lopinavirritonavir
primari
endpoint
clearanc
rate
day
treatment
secondari
endpoint
time
clearanc
patient
novaferon
inhibit
viral
replic
infect
cell
ec
ngml
protect
healthi
cell
infect
ec
ngml
result
lopinavirritonavir
group
significantli
higher
clearanc
rate
day
lopinavirritonavir
group
p
p
median
time
clearanc
day
day
day
three
group
respect
suggest
time
clearanc
novaferon
novaferon
plu
lopinavirritonavir
group
compar
lopinavirritonavir
group
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
infect
novel
coronaviru
becom
global
pandem
caus
confirm
case
death
effect
antivir
drug
might
lead
earlier
clearanc
turn
help
slow
stop
progress
diseas
cours
patient
elimin
viru
patient
earli
stage
would
also
contribut
reduct
transmiss
deadli
viru
immedi
avail
establish
safeti
profil
approv
antivir
drug
target
desir
find
effect
drug
shortest
time
possibl
howev
none
promis
antivir
drug
prove
effect
yet
publish
find
antivir
treatment
base
individu
case
report
cellular
antivir
result
despit
lack
convinc
evid
lopinavirritonavir
quickli
select
recommend
antivir
drug
china
sinc
januari
far
limit
observ
lopinavirritonavir
coronaviru
sar
patient
report
result
recent
complet
trial
lopinavirritonavir
patient
sever
gener
disappoint
outcom
show
signific
antivir
effect
without
effect
antivir
drug
health
care
worker
altern
choic
mainli
reli
support
symptomat
treatment
manag
patient
rapid
spread
daili
increas
larg
death
number
perhap
repres
one
biggest
medic
human
challeng
even
critic
two
month
ago
find
antivir
drug
clinic
evid
patient
novaferon
novel
antivir
protein
drug
approv
treatment
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
novaferon
similar
properti
human
interferon
antivir
activ
greatli
improv
least
time
potent
human
interferon
antivir
efficaci
novaferon
demonstr
clinic
studi
conduct
china
april
novaferon
approv
china
former
cfda
chines
food
drug
administr
treatment
chronic
hepat
b
novaferon
protein
nonproprietari
name
temporarili
defin
recombin
cytokin
genederiv
protein
inject
chines
pharmacopeia
committe
recommend
intern
nonproprietari
name
rinn
avail
yet
conveni
purpos
novaferon
use
drug
name
studi
present
studi
specif
focus
observ
antivir
effect
novaferon
first
determin
whether
novaferon
abl
inhibit
cellular
level
conduct
random
openlabel
parallel
group
trial
explor
antivir
effect
novaferon
patient
observ
clearanc
rate
differ
time
treatment
period
primari
endpoint
clearanc
rate
day
secondari
endpoint
median
time
reach
clearanc
patient
popular
standard
antivir
drug
china
lopinavirritonavir
includ
studi
serv
control
comparison
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
vitro
experi
conduct
biosafeti
laboratori
chines
center
diseas
control
prevent
chines
cdc
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
observ
whether
previou
treatment
vero
cell
novaferon
protect
cell
viral
entri
exposur
pretreat
cell
later
detail
oper
procedur
ident
descript
except
step
order
chang
allow
observ
prevent
effect
novaferon
briefli
blank
vero
cell
incub
seri
concentr
novaferon
hour
supernat
contain
novaferon
remov
pretreat
vero
cell
expos
incub
ctanncov
wuhan
strain
hour
supernat
contain
remov
fresh
medium
ad
cell
incub
hour
l
supernat
taken
well
total
viral
rna
supernat
measur
use
method
describ
ct
number
obtain
vero
cell
without
pretreat
novaferon
consid
decreas
ct
number
obtain
pretreat
vero
cell
variou
concentr
novaferon
use
calcul
inhibit
percentag
prevent
effect
novaferon
determin
observ
viral
rna
reduct
inth
cell
pretreat
novaferon
ec
novaferon
observ
prevent
effect
decid
accordingli
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
studi
origin
design
multicent
studi
across
hospit
changsha
citi
citi
hunan
provinc
china
howev
per
govern
order
patient
hospit
changsha
citi
reloc
first
hospit
changsha
design
treatment
center
patient
changsha
citi
hospit
citi
hunan
provinc
abl
particip
due
variou
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
antivir
effect
assess
day
day
day
start
drug
administr
antivir
drug
involv
studi
novaferon
temporari
nonproprietari
name
recombin
cytokin
genederiv
protein
inject
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
grade
scale
determin
sever
peak
level
sar
viru
around
day
onset
viral
level
began
decreas
without
effect
antivir
treatment
sar
patient
consid
homolog
gene
sequenc
sar
assum
intervent
antivir
drug
patient
would
like
enhanc
shorten
time
viral
clearanc
regard
primari
endpoint
studi
decid
clearanc
rate
patient
assess
day
antivir
treatment
secondari
endpoint
time
till
clearanc
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
statist
analysi
perform
intenttotreat
basi
patient
random
treat
least
studi
medic
includ
primari
analysi
patient
demograph
inform
baselin
diseas
characterist
qualit
variabl
compar
among
treatment
group
use
chisquar
test
quantit
variabl
compar
use
anova
model
overal
differ
among
three
treatment
group
test
base
null
hypothesi
three
group
altern
hypothesi
least
one
group
differ
therefor
pairwis
comparison
perform
baselin
characterist
primari
endpoint
clearanc
rate
estim
rate
calcul
base
binomi
distribut
differ
treatment
group
test
use
chisquar
test
control
overal
signific
level
studi
three
pairwis
comparison
primari
endpoint
perform
twosid
alpha
use
close
test
procedur
accord
follow
order
novaferon
plu
lopinavirritonavir
vs
lopinavirritonavir
alon
novaferon
alon
vs
lopinavirritonavir
alon
novaferon
plu
lopinavirritonavir
vs
novaferon
alon
secondari
endpoint
time
clearanc
median
time
group
estim
use
kaplanmei
method
treatment
differ
test
use
logrank
test
test
twosid
p
valu
less
consid
indic
statist
signific
analysi
conduct
use
sa
miss
clearanc
statu
last
observ
carri
forward
locf
analysi
present
primari
analysi
purpos
sensit
analys
complet
case
analysi
worst
case
imput
method
also
perform
worst
case
imput
miss
statu
replac
posit
plan
sampl
size
patient
patient
per
group
determin
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
base
statist
consider
advers
event
report
grade
use
toxic
grade
scale
determin
sever
incid
advers
event
summar
descript
without
formal
statist
test
shown
data
indic
novaferon
effect
inhibit
viral
replic
within
cell
addit
healthi
vero
cell
previous
treat
novaferon
obtain
abil
resist
viral
entri
indic
reduct
viral
rna
exposur
treat
cell
later
novaferon
exhibit
prevent
effect
effici
ec
ngml
lower
ec
inhibit
replic
infect
cell
data
suggest
novaferon
inhibit
viral
replic
cell
enabl
healthi
cell
resist
viral
entri
total
patient
moder
sever
ill
assess
elig
criteria
patient
exclud
patient
random
studi
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
sever
ill
appar
differ
among
group
respect
patient
demograph
baselin
characterist
tabl
summar
complet
rtpcr
test
result
patient
day
day
day
start
drug
administr
neg
result
nucleic
acid
detect
test
sampl
serv
indic
vivo
clearanc
patient
clearanc
rate
day
day
day
three
treatment
group
present
compar
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
novaferon
plu
lopinavirritonavir
group
lopinavirritonavir
group
statist
signific
differ
group
median
time
clearanc
day
day
day
analys
base
complet
case
analysi
worst
case
clearanc
rate
show
littl
differ
locf
analysi
statist
conclus
treatment
comparison
remain
sever
advers
event
sae
associ
test
antivir
drug
observ
report
grade
advers
event
ae
describ
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
observ
period
matter
whether
exhibit
good
poor
none
effect
lopinavirritonavir
studi
serv
control
allow
us
assess
antivir
effect
novaferon
patient
consist
laboratori
find
inhibit
viral
replic
novaferon
cellular
level
effici
indic
low
ec
ngml
interestingli
healthi
cell
pretreat
novaferon
obtain
abil
absenc
novaferon
resist
viral
entri
cell
treat
cell
expos
later
ec
ngml
might
worth
explor
potenti
use
novaferon
prevent
agent
high
risk
popul
especi
health
care
worker
routin
contact
patient
viral
load
patient
report
reach
peak
level
around
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
patient
novaferon
treatment
unlik
relat
natur
diseas
cours
rather
observ
enhanc
clearanc
appar
reflect
antivir
effect
novaferon
observ
patient
studi
sever
limit
first
observ
done
one
hospit
one
citi
second
sampl
size
rel
small
base
statist
consider
limit
avail
patient
changsha
citi
third
unexpect
difficulti
associ
outbreak
compromis
qualiti
studi
exampl
highli
possibl
advers
event
underreport
due
lack
medic
staff
risk
situat
howev
limit
nt
chang
overal
conclus
thisrandom
trial
antivir
assess
strictli
perform
accord
vigor
standard
novaferon
exhibit
effect
cellular
level
patient
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
